Current Report Filing (8-k)
March 02 2018 - 1:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
February 27,
2018
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
000-52138
|
20-2000871
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code
(250)
765-6424
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2
of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [ ]
Item 1.01
|
Entry into a Material Definitive Agreement
|
On February 26, 2018, Lexaria announced it has entered an
agreement with NeutriSci International Inc. such that NeutriSci now owns 100% of
Ambarii Trade Corporation (Ambarii), and Lexaria has granted to NeutriSci an
Intellectual Property License and Supply Agreement for the manufacturing and
sale of CBD based products.
- 2 -
Under the License Agreement, NeutriSci will continue the
development and sales of its proprietary sublingual mouth-melt consumer products
that incorporate Lexarias technology for enhancing palatability and
bioavailability of beneficial non-psychoactive cannabinoids in NeutriScis
existing and pipeline product formats. Lexaria will earn ongoing royalty
revenues from the sales generated by these products.
On February 27, 2018 Lexaria announced it has entered a
definitive technology licensing agreement with Los Angeles-based, privately-held
Biolog, Inc. whereby Lexaria is providing its patented DehydraTECH
TM
technology to empower a unique set of next-generation food and beverage cannabis
infusion products to be sold in the United States.
Biolog intends to launch new products of this type to deliver
DehydraTECH
TM
enabled CBD from hemp and/or vitamins in products
available nationwide. Biolog will also launch new DehydraTECH
TM
enabled products in those states where it is permissible to do so delivering
cannabinoids from cannabis. All product lines will offer superior palatability
and bioabsorption, as well as fast action powered by DehyrdaTECH
TM
.
Item 7.01
|
Regulation FD Disclosure
|
A copy of the news release announcing that Lexaria has entered
a definitive technology licensing agreement with NeutriSci is filed as exhibit
99.1 to this current report and is hereby incorporated by reference.
A copy of the news release announcing that Lexaria has entered
a definitive technology licensing agreement with Biolog is filed as exhibit 99.2
to this current report and is hereby incorporated by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
/s/ Chris
Bunka
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
- 3 -